Loading clinical trials...
Loading clinical trials...
Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care
Conditions
Interventions
EGF Vaccine
Locations
51
Bulgaria
"Multiprofile Hospital for Active Treatment (MHAT)-Dobrich" AD
Dobrich, Bulgaria
MHAT for Women's Health-Nadezhda"OOD
Sofia, Bulgaria
Nemocnice Na Pleši s.r.o. Oddelení klinické onkologie a radioterapie
Nová Ves pod Pleší, Czechia
Pardubická krajská nemocnice, a.s.c
Pardubice, Czechia
Thomayerova nemocnice
Prague, Czechia
Cancer Center of Adjara
Batumi, Georgia
Start Date
May 1, 2015
Primary Completion Date
May 1, 2019
Completion Date
September 6, 2019
Last Updated
September 10, 2019
NCT06667908
NCT04165798
NCT06875310
NCT07046923
NCT07222566
NCT06667076
Lead Sponsor
Bioven Europe
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions